• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab

tetano

Editor, Senior Moderator
PLoS One


. 2021 Aug 19;16(8):e0255976.
doi: 10.1371/journal.pone.0255976. eCollection 2021.
COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab


Sanzio Dimai[SUP] 1 2 [/SUP], Lukas Semmler[SUP] 1 3 [/SUP], Ashok Prabhu[SUP] 1 3 [/SUP], Harald Stachelscheid[SUP] 4 [/SUP], Judith Huettemeister[SUP] 1 [/SUP], Sandra C Klaucke[SUP] 5 [/SUP], Philipp Lacour[SUP] 1 3 [/SUP], Florian Blaschke[SUP] 1 3 [/SUP], Jan Kruse[SUP] 6 [/SUP], Abdul Parwani[SUP] 1 3 [/SUP], Leif-Hendrik Boldt[SUP] 1 3 [/SUP], Lars Bullinger[SUP] 7 [/SUP], Burkert M Pieske[SUP] 1 3 4 8 [/SUP], Frank R Heinzel[SUP] 1 3 [/SUP], Felix Hohendanner[SUP] 1 3 4 [/SUP]



Affiliations

Abstract

Background: Cardiac injury associated with cytokine release frequently occurs in SARS-CoV-2 mediated coronavirus disease (COVID19) and mortality is particularly high in these patients. The mechanistic role of the COVID19 associated cytokine-storm for the concomitant cardiac dysfunction and associated arrhythmias is unclear. Moreover, the role of anti-inflammatory therapy to mitigate cardiac dysfunction remains elusive.
Aims and methods: We investigated the effects of COVID19-associated inflammatory response on cardiac cellular function as well as its cardiac arrhythmogenic potential in rat and induced pluripotent stem cell derived cardiomyocytes (iPS-CM). In addition, we evaluated the therapeutic potential of the IL-1β antagonist Canakinumab using state of the art in-vitro confocal and ratiometric high-throughput microscopy.
Results: Isolated rat ventricular cardiomyocytes were exposed to control or COVID19 serum from intensive care unit (ICU) patients with severe ARDS and impaired cardiac function (LVEF 41±5%; 1/3 of patients on veno-venous extracorporeal membrane oxygenation; CK 154±43 U/l). Rat cardiomyocytes showed an early increase of myofilament sensitivity, a decrease of Ca2+ transient amplitudes and altered baseline [Ca2+] upon exposure to patient serum. In addition, we used iPS-CM to explore the long-term effect of patient serum on cardiac electrical and mechanical function. In iPS-CM, spontaneous Ca2+ release events were more likely to occur upon incubation with COVID19 serum and nuclear as well as cytosolic Ca2+ release were altered. Co-incubation with Canakinumab had no effect on pro-arrhythmogenic Ca2+ release or Ca2+ signaling during excitation-contraction coupling, nor significantly influenced cellular automaticity.
Conclusion: Serum derived from COVID19 patients exerts acute cardio-depressant and chronic pro-arrhythmogenic effects in rat and iPS-derived cardiomyocytes. Canakinumab had no beneficial effect on cellular Ca2+ signaling during excitation-contraction coupling. The presented method utilizing iPS-CM and in-vitro Ca2+ imaging might serve as a novel tool for precision medicine. It allows to investigate cytokine related cardiac dysfunction and pharmacological approaches useful therein.
 
Back
Top Bottom